메뉴 건너뛰기
BMJ
Volumn 316, Issue 7139, 1998, Pages 1181-1182
Tamoxifen for the prevention of breast cancer: Important questions remain unanswered, and existing trials should continue
Author keywords

[No Author keywords available]
Indexed keywords

TAMOXIFEN;
EID: 0032542924     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7139.1181     Document Type: Editorial
Times cited : (12)
References (7)
  • 1
    • 0030321284 scopus 로고    scopus 로고
    • IARC Monographs on the evaluation of carcinogenic risks to humans
    • Lyons: International Agency for Research on Cancer
    • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 66. Some pharmaceutical drugs. Lyons: International Agency for Research on Cancer, 1996: 253-366.
    • (1996) Some pharmaceutical drugs , vol.66 , pp. 253-366
  • 2
    • 0027290493 scopus 로고
    • Tamoxifen for the primary prevention of breast cancer: A review and critique of the concept and trial
    • Bush TL, Helzlsouer KJ. Tamoxifen for the primary prevention of breast cancer: A review and critique of the concept and trial. Epidemiol Rev 1993; 15: 233-243.
    • (1993) Epidemiol Rev , vol.15 , pp. 233-243
    • Bush, T.L.1    Helzlsouer, K.J.2
  • 3
    • 0032542875 scopus 로고    scopus 로고
    • Breast cancer trial stopped early
    • Josefson D. Breast cancer trial stopped early. BMJ 1998; 316: 1187.
    • (1998) BMJ , vol.316 , pp. 1187
    • Josefson, D.1
  • 4
    • 85007730045 scopus 로고    scopus 로고
    • PDQ Supportive Care/Screening/Prevention Information. Cancer Net, National Cancer Institute, April http://cancernet.nih.nci.gov/pdq.htm
    • Prevention of breast cancer. PDQ Supportive Care/Screening/Prevention Information. Cancer Net, National Cancer Institute, April 1998 http://cancernet.nih.nci.gov/pdq.htm
    • (1998) Prevention of breast cancer
  • 5
    • 0026557343 scopus 로고
    • Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy. 133 randomized trials involving 31 000 recurrences and 25 000 deaths among 75 000 women
    • 71-85.
    • Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy. 133 randomized trials involving 31 000 recurrences and 25 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
    • (1992) Lancet , vol.339 , pp. 1-15
  • 6
    • 10344238569 scopus 로고    scopus 로고
    • Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
    • Fisher B, Dignam J, Bryant J, DeCillis A, Lawrence Wickerham D, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529-1542.
    • (1996) J Natl Cancer Inst , vol.88 , pp. 1529-1542
    • Fisher, B.1    Dignam, J.2    Bryant, J.3    DeCillis, A.4    Lawrence, W.D.5
  • 7
    • 0030792818 scopus 로고    scopus 로고
    • Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
    • Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollack MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997; 80: 435-444.
    • (1997) Cancer , vol.80 , pp. 435-444
    • Karp, S.E.1    Tonin, P.N.2    Begin, L.R.3    Martinez, J.J.4    Zhang, J.C.5    Pollack, M.N.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.